SCHEDULE: Nantahala Capital Boosts Bioventus Stake to 9.03%

Nantahala Capital Management and its managing members have reported a 9.03% beneficial ownership stake in Bioventus Inc. Class A Common Stock as of December 31, 2025.

Summary

• Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, collectively reported beneficial ownership of 6,047,403 shares of Bioventus Inc. Class A Common Stock.
• This ownership represents 9.03% of the total outstanding Class A Common Stock.
• The shares are held by funds and separately managed accounts under Nantahala's control.
• The reporting persons share both voting and dispositive power over all 6,047,403 shares, with no sole voting or dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Bioventus Inc., except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial stake by an investment adviser suggests a belief in Bioventus's value, although the filing explicitly disclaims intent to influence control, with the exception of potential board nominations.

Positives

• A significant 9.03% stake by an institutional investment adviser like Nantahala Capital Management can signal confidence in Bioventus Inc.'s long-term prospects.
• The shared voting and dispositive power among Nantahala and its managing members indicates a unified investment strategy.

Negatives

• The filing itself does not present any direct negative information about Bioventus Inc.

Risks

• The filing does not detail specific risks related to Bioventus Inc.'s operations or financial health.
• The only potential 'risk' mentioned is the possibility of activities solely in connection with a nomination under Rule 14a-11, which could imply future engagement regarding board composition.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that significant institutional ownership, particularly by an investment adviser like Nantahala Capital Management, often indicates a belief in the underlying value or future growth potential of a company within its sector. For Bioventus, a medical technology company, such a stake could be interpreted as a positive signal regarding its product pipeline, market position, or operational efficiency compared to peers.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could instill confidence among existing shareholders and attract new investors, potentially influencing share price.
• Management: While the filing disclaims intent to influence control, the mention of potential Rule 14a-11 nominations suggests that management may face increased scrutiny or engagement from this significant shareholder.

Next Steps

• Potential future engagement by Nantahala Capital Management related to board nominations under Rule 14a-11.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a substantial stake, which is generally a positive signal. However, without additional information on Bioventus's financial performance or strategic direction, a 'hold' recommendation is prudent, acknowledging the positive signal while awaiting further operational or financial updates from the company. The explicit disclaimer regarding control influence, with the exception of potential board nominations, suggests a long-term investment rather than immediate activist pressure.

Keywords

Bioventus Inc., Nantahala Capital Management, Schedule 13G, beneficial ownership, Class A Common Stock, institutional investor, equity stake, investment adviser, Wilmot B. Harkey, Daniel Mack